Literature DB >> 19047135

Chemotherapy induces tumor clearance independent of apoptosis.

Jennifer L Guerriero1, Dara Ditsworth, Yongjun Fan, Fangping Zhao, Howard C Crawford, Wei-Xing Zong.   

Abstract

Dysregulation of apoptosis is associated with the development of human cancer and resistance to anticancer therapy. The ultimate goal of cancer treatment is to selectively induce cancer cell death and overcome drug resistance. A deeper understanding of how a given chemotherapy affects tumor cell death is needed to develop strategically designed anticancer agents. Here, we use a xenograft mouse tumor system generated from genetically defined cells deficient in apoptosis to examine the involvement of multiple forms of cell death induced by cyclophosphamide (CP), a DNA alkylating agent commonly used in chemotherapy. We find that although apoptosis facilitates tumor regression, it is dispensable for complete tumor regression as other forms of cell death are activated. Sporadic necrosis is observed in both apoptosis-competent and deficient tumors evident by tumor cell morphology, extracellular release of high mobility group box 1 protein, and activation of innate immune cells in CP-treated tumors. Our findings indicate that in apoptosis-deficient tumors, necrosis may play a fundamental role in tumor clearance by stimulating the innate immune response.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19047135      PMCID: PMC2596650          DOI: 10.1158/0008-5472.CAN-08-2452

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  15 in total

Review 1.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

Review 2.  Inflammation and necrosis promote tumour growth.

Authors:  Jukka Vakkila; Michael T Lotze
Journal:  Nat Rev Immunol       Date:  2004-08       Impact factor: 53.106

3.  How many ways to die? How many different models of cell death?

Authors:  G Melino; R A Knight; P Nicotera
Journal:  Cell Death Differ       Date:  2005-11       Impact factor: 15.828

Review 4.  The Bcl-2 apoptotic switch in cancer development and therapy.

Authors:  J M Adams; S Cory
Journal:  Oncogene       Date:  2007-02-26       Impact factor: 9.867

Review 5.  Addicted to death: invasive cancer and the immune response to unscheduled cell death.

Authors:  Herbert J Zeh; Michael T Lotze
Journal:  J Immunother       Date:  2005 Jan-Feb       Impact factor: 4.456

6.  Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF.

Authors:  V A Fadok; D L Bratton; A Konowal; P W Freed; J Y Westcott; P M Henson
Journal:  J Clin Invest       Date:  1998-02-15       Impact factor: 14.808

Review 7.  The role of apoptosis in cancer development and treatment response.

Authors:  J Martin Brown; Laura D Attardi
Journal:  Nat Rev Cancer       Date:  2005-03       Impact factor: 60.716

Review 8.  Role of autophagy in cancer.

Authors:  Robin Mathew; Vassiliki Karantza-Wadsworth; Eileen White
Journal:  Nat Rev Cancer       Date:  2007-12       Impact factor: 60.716

9.  Activation mechanisms of mafosfamide and the role of thiols in cyclophosphamide metabolism.

Authors:  C H Kwon; R F Borch; J Engel; U Niemeyer
Journal:  J Med Chem       Date:  1987-02       Impact factor: 7.446

10.  Gadolinium induces macrophage apoptosis.

Authors:  J P Mizgerd; R M Molina; R C Stearns; J D Brain; A E Warner
Journal:  J Leukoc Biol       Date:  1996-02       Impact factor: 4.962

View more
  23 in total

Review 1.  Chemotherapy and signaling: How can targeted therapies supercharge cytotoxic agents?

Authors:  Tetyana V Bagnyukova; Ilya G Serebriiskii; Yan Zhou; Elizabeth A Hopper-Borge; Erica A Golemis; Igor Astsaturov
Journal:  Cancer Biol Ther       Date:  2010-11-01       Impact factor: 4.742

2.  Non-apoptotic routes to defeat cancer.

Authors:  Jennifer L Guerriero; Dara Ditsworth; Wei-Xing Zong
Journal:  Oncoimmunology       Date:  2012-01-01       Impact factor: 8.110

3.  Intermittent metronomic drug schedule is essential for activating antitumor innate immunity and tumor xenograft regression.

Authors:  Chong-Sheng Chen; Joshua C Doloff; David J Waxman
Journal:  Neoplasia       Date:  2014-01       Impact factor: 5.715

4.  Squamous cell carcinoma antigen 1 promotes caspase-8-mediated apoptosis in response to endoplasmic reticulum stress while inhibiting necrosis induced by lysosomal injury.

Authors:  Erica Ullman; Ji-An Pan; Wei-Xing Zong
Journal:  Mol Cell Biol       Date:  2011-05-16       Impact factor: 4.272

5.  The CCL2 chemokine is a negative regulator of autophagy and necrosis in luminal B breast cancer cells.

Authors:  Wei Bin Fang; Min Yao; Iman Jokar; Nabil Alhakamy; Cory Berkland; Jin Chen; Dana Brantley-Sieders; Nikki Cheng
Journal:  Breast Cancer Res Treat       Date:  2015-03-06       Impact factor: 4.872

6.  Actinomycin D synergistically enhances the efficacy of the BH3 mimetic ABT-737 by downregulating Mcl-1 expression.

Authors:  Kristen E Olberding; Xiaoli Wang; Yanglong Zhu; Jianmin Pan; Shesh N Rai; Chi Li
Journal:  Cancer Biol Ther       Date:  2010-11-01       Impact factor: 4.742

7.  VEGF receptor inhibitors block the ability of metronomically dosed cyclophosphamide to activate innate immunity-induced tumor regression.

Authors:  Joshua C Doloff; David J Waxman
Journal:  Cancer Res       Date:  2012-01-11       Impact factor: 12.701

8.  DNA alkylating therapy induces tumor regression through an HMGB1-mediated activation of innate immunity.

Authors:  Jennifer L Guerriero; Dara Ditsworth; Joseph M Catanzaro; Gregory Sabino; Martha B Furie; Richard R Kew; Howard C Crawford; Wei-Xing Zong
Journal:  J Immunol       Date:  2011-02-07       Impact factor: 5.422

9.  Human ALKBH7 is required for alkylation and oxidation-induced programmed necrosis.

Authors:  Dragony Fu; Jennifer J Jordan; Leona D Samson
Journal:  Genes Dev       Date:  2013-05-10       Impact factor: 11.361

10.  Magnetic Resonance Imaging Is More Sensitive Than PET for Detecting Treatment-Induced Cell Death-Dependent Changes in Glycolysis.

Authors:  Richard L Hesketh; Jiazheng Wang; Alan J Wright; David Y Lewis; Alice E Denton; Richard Grenfell; Jodi L Miller; Robert Bielik; Marcel Gehrung; Maria Fala; Susana Ros; Bangwen Xie; De-En Hu; Kevin M Brindle
Journal:  Cancer Res       Date:  2019-05-14       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.